1. β-Defensins: Work in Progress
- Author
-
Vincenza De Gregorio, Iole Paoletti, Elisabetta Buommino, Alessandra Fusco, Brunella Perfetto, Adone Baroni, Giovanna Donnarumma, Donnarumma Giovanna, Paoletti Iole, Fusco Alessandra, Perfetto Brunella, Buommino Elisabetta, de Gregorio Vincenza, Baroni Adone, Donelli G., Donnarumma, Giovanna, Paoletti, Iole, Fusco, Alessandra, Perfetto, Brunella, Buommino, Elisabetta, de Gregorio, Vincenza, Baroni, Adone, and Donelli G
- Subjects
0301 basic medicine ,Innate immune system ,medicine.drug_class ,Chemistry ,Inflammatory mediator ,Antibiotics ,Antimicrobial peptides ,Wound healing ,Beta defensin ,Antimicrobial ,Cell biology ,Proinflammatory cytokine ,Angiogenesi ,030207 dermatology & venereal diseases ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine ,Cytotoxicity ,Defensin ,Cancer - Abstract
Defensins are a group of antimicrobial peptides (AMPs) found in different living organisms, and are involved in the first line of defense in the innate immune response against pathogens. The increase in the resistance of bacteria to conventional antibiotics and the need for new antibiotics has stimulated interest in the use of AMPs as new therapeutic agents. The inducible nature of human defensin genes suggests that it is possible to increase the endogenous production by utilizing small molecules of various origins to enhance, even selectively, the expression of these peptides. In the light of their role in immunomodulation, angiogenesis, wound healing, inflammation and cancer, as well as their antimicrobial activity, it is possible induce their expression or create analogs with increased specific activity or various degrees of selectivity, or obtain human defensins with genetic engineering to optimize the potency and safety in order to reduce cytotoxicity and potential proinflammatory activity and susceptibility to protease and salt. Restoring the balance between immunostimulating and immunosuppressive molecules may be an important strategy to correct expression defects in specific diseases.
- Published
- 2016